Plus Therapeutics, Inc.
PSTV
$0.26
-$0.01-1.92%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -10.49% | -8.16% | -3.49% | -14.43% | 18.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -10.49% | -8.16% | -3.49% | -14.43% | 18.54% |
| Cost of Revenue | -20.80% | -31.86% | -25.66% | 1.09% | 9.18% |
| Gross Profit | 33.43% | 56.69% | 48.65% | -28.97% | 0.44% |
| SG&A Expenses | 22.06% | 20.67% | 14.25% | 24.12% | 16.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.04% | -8.17% | -7.77% | 11.99% | 12.53% |
| Operating Income | -4.10% | 8.17% | 9.44% | -25.50% | -10.31% |
| Income Before Tax | -72.49% | -59.69% | -43.82% | -130.36% | 2.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -72.49% | -59.69% | -43.82% | -130.36% | 2.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -72.49% | -59.69% | -43.82% | -130.36% | 2.54% |
| EBIT | -4.10% | 8.17% | 9.44% | -25.50% | -10.31% |
| EBITDA | -7.45% | 8.37% | 10.89% | -24.80% | -8.90% |
| EPS Basic | -1,329.44% | -1,141.10% | -894.63% | -866.42% | 54.09% |
| Normalized Basic EPS | -1,745.59% | -1,497.00% | -1,176.84% | -1,139.03% | 54.09% |
| EPS Diluted | -1,169.79% | -1,020.74% | -817.49% | -874.04% | 48.29% |
| Normalized Diluted EPS | -1,924.40% | -1,628.02% | -1,259.11% | -1,133.42% | 58.05% |
| Average Basic Shares Outstanding | 1,007.47% | 608.18% | 248.12% | 55.79% | 111.43% |
| Average Diluted Shares Outstanding | 1,377.09% | 1,084.94% | 888.77% | 84.94% | 145.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |